The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Feb. 16, 2010

Filed:

Dec. 02, 2005
Applicants:

Jianhua Shen, Shanghai, CN;

Hualiang Jiang, Shanghai, CN;

Xu Shen, Shanghai, CN;

Jianping Zuo, Shanghai, CN;

Xiaomin Luo, Shanghai, CN;

Donglu Bai, Shanghai, CN;

Jingkang Shen, Shanghai, CN;

Kaixian Chen, Shanghai, CN;

Chunshan Gui, Shanghai, CN;

Lili Chen, Shanghai, CN;

Jing Chen, Shanghai, CN;

Yifu Yang, Shanghai, CN;

Xianhan Zhuang, Shanghai, CN;

Yiming Yang, Shanghai, CN;

Xuchang He, Shanghai, CN;

Hong Liu, Shanghai, CN;

Bing Xiong, Shanghai, CN;

Haibin Luo, Shanghai, CN;

Tao Sun, Shanghai, CN;

Fei YE, Shanghai, CN;

Inventors:

Jianhua Shen, Shanghai, CN;

Hualiang Jiang, Shanghai, CN;

Xu Shen, Shanghai, CN;

Jianping Zuo, Shanghai, CN;

Xiaomin Luo, Shanghai, CN;

Donglu Bai, Shanghai, CN;

Jingkang Shen, Shanghai, CN;

Kaixian Chen, Shanghai, CN;

Chunshan Gui, Shanghai, CN;

Lili Chen, Shanghai, CN;

Jing Chen, Shanghai, CN;

Yifu Yang, Shanghai, CN;

Xianhan Zhuang, Shanghai, CN;

Yiming Yang, Shanghai, CN;

Xuchang He, Shanghai, CN;

Hong Liu, Shanghai, CN;

Bing Xiong, Shanghai, CN;

Haibin Luo, Shanghai, CN;

Tao Sun, Shanghai, CN;

Fei Ye, Shanghai, CN;

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 31/165 (2006.01);
U.S. Cl.
CPC ...
Abstract

The present invention discloses 3D-structure of SARS-CoV Viral 3CL Protease obtained through molecular simulation. The 3D-structure is used as a drug target for screening the existing medical database CMC (Comprehensive Medicinal Chemistry, MDL Information System, Inc.), and a group of compounds which have the activity of inhibiting SARS-CoV virus 3CL Protease are found. Cinanserin was tested at molecular and viral levels, and it was found to be able to inhibit the SARS-CoV viral 3CL protease and SARS-CoV viruses. Cinanserin analogs were synthesized and tested at molecular and viral levels, they were found to be able to inhibit the SARS-CoV virus 3CL Protease and SARS-CoV viruses, and may be used for treating and/or preventing SARS-CoV virus infection.


Find Patent Forward Citations

Loading…